PRESS RELEASE

22nd November, 2019, Vadodara, India

Alembic Pharmaceuticals receives USFDA Approvals

Alembic Pharmaceuticals Limited today announced that the Company has received approval from US Food & Drug Administration (USFDA) for its following Abbreviated New Drug Applications (ANDAs):

USFDA Approval	Name of the ANDAs	Dosage	Equivalent to reference listed drug product (RLD)	Usage	Estimated Market Size
Final	Deferasirox Tablets	90 mg and 360 mg	Jadenu Tablets, 90 mg and 360 mg, of Novartis Pharmaceuticals Corporation (Novartis).	Treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older.	US$ 415 million for twelve months ending December 2018 according to IQVIA.
Final	Deferasirox Tablets for Oral Suspension	125 mg, 250 mg, and 500 mg	Exjade Tablets for Oral Suspension, 125 mg, 250 mg, and 500 mg, of Novartis Pharmaceuticals Corporation (Novartis).	Same as above.	US$ 135 million for twelve months ending December 2018 according to IQVIA.
Tentative	Deferasirox Tablets	180 mg	Jadenu Tablets, 180 mg, of Novartis Pharmaceuticals Corporation (Novartis).	Same as above.	US$59 million for twelve months ending December 2018 according to IQVIA.

Alembic now has a total of 107 ANDA approvals (95 final approvals and 12 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries